| Literature DB >> 26297745 |
Susan Bull1, Nia Roberts2, Michael Parker2.
Abstract
There is increasing support for sharing individual-level data generated by medical and public health research. This scoping review of empirical research and conceptual literature examined stakeholders' perspectives of ethical best practices in data sharing, particularly in low- and middle-income settings. Sixty-nine empirical and conceptual articles were reviewed, of which, only five were empirical studies and eight were conceptual articles focusing on low- and middle-income settings. We conclude that support for sharing individual-level data is contingent on the development and implementation of international and local policies and processes to support ethical best practices. Further conceptual and empirical research is needed to ensure data sharing policies and processes in low- and middle-income settings are appropriately informed by stakeholders' perspectives.Entities:
Keywords: biomedical research ethics; clinical research; data access; data release; data sharing; health policy; low-income countries; middle-income countries; privacy; research data; research governance; systematic review
Mesh:
Year: 2015 PMID: 26297745 PMCID: PMC4548478 DOI: 10.1177/1556264615594767
Source DB: PubMed Journal: J Empir Res Hum Res Ethics ISSN: 1556-2646 Impact factor: 1.742
Summary of Potential Benefits of and Concerns About Data Sharing.
| Reasons to share individual-level data | Concerns about sharing individual-level data |
|---|---|
| To improve science Enable verification, replication, and expansion of research results Address biases, deficiencies, and dishonesty in research Enable novel analyses and increase study power Improve meta-analyses Maximize data use, particularly for datasets that cannot be replicated Inform research design and research funding Improve teaching resources Increase primary data producers’ academic profiles and collaboration opportunities | May hamper science Reputational harms of critical secondary analyses Consequences of flawed/poor quality secondary analyses Reduction of incentives for primary research Increased incentives to conduct short-term research rather than long-term research Opportunity costs of curating and sharing data |
| To improve health Inform health care planning and allocation Inform regulatory review Improve evidence base for clinical decision making Improve use of health care resources Improve patient care | May hamper health Effects of flawed secondary analyses on scientific evidence base Burden of evaluating validity of secondary analyses Effects of second-guessing regulatory procedures, policies, and processes |
| Explicit moral claims Importance of maximizing the value and utility of data Promotion of scientific values Promotion of best practices in research conduct, analysis, and reporting Demonstration of respect for research participants Promotion of the public good | Explicit ethical issues Protection of participants’ privacy and confidentiality Validity of consent, including broad consent Potential harms of secondary research for research participants including discrimination and stigma Researchers’ ability to fulfill commitments made to research participants during data collection Effects of moral distance and limited awareness of the context in which data were collected Potential impacts on public trust and confidence of conflicting analyses Balancing the interests of differing stakeholders in data sharing Making best use of limited research resources |
| Barriers to sharing Costs of developing and maintaining appropriate expertise and infrastructure Curation costs Ownership, intellectual property rights, and commercial confidentiality Lack of policies and processes |
Figure 1.PRISMA 2009 flow diagram of the scoping review.
Source. Moher, Liberati, Tetzlaff, Altman, and the PRISMA Group (2009).
Articles Included in the Scoping Review.
| Type of Article | Articles of general relevance | Articles of particular relevance in low-and middle-income settings |
|---|---|---|
| Empirical research articles | ||
| Articles focusing on ethics, policy, and governance issues |
Empirical Research Into Stakeholders’ Experiences and Perspectives.
| Author, publication year | Study aim | Sample | Methods | Key findings |
|---|---|---|---|---|
| Determine opinions of making original data available for alternative analysis. | 21 (84%) of 25 invitees from pharmaceutical companies with an interest in rheumatology. Locations of respondents not discussed. | Letter with brief rationale for sharing data and asking whether it would be useful for trial data related to a publication to be shared via a databank and if so, what issues might arise. | 5 (24%) of respondents were in favor of sharing data via a databank and 16 (76%) were not. | |
| Investigate the preparedness of researchers to share their data. | 21 (72%) of 29 inquiries sent to corresponding authors of research articles in the | Emailed specific request to reanalyze the data used in a published study (15) or a general inquiry about willingness to share data from a published study(14). | 9 (60%) of authors receiving specific requests and 12 (86%) of authors receiving general requests responded. Of the 21 responding authors, one shared the dataset and one was prepared to share the dataset without further conditions, 10 were prepared to release the data in principle subject to further discussions/conditions, three would not release data (suggesting they conduct new analyses themselves or that sufficient data were available in the articles), and six were ultimately non-committal. | |
| To test effects of journal policies requiring data to be shared. | 10 requests for datasets from corresponding authors of research articles in PLoS Medicine or PLoS Clinical Trials | An emailed request for a dataset to test a pre-specified hypothesis about prediction modeling. | Two authors had changed institution and could not be contacted. | |
| To investigate clinical trialists’ opinions and experiences of sharing data with non-collaborating investigators. | 317 (46%) of 683 corresponding authors of clinical trials published in 2010 or 2011 in one of the six highest impact general medical journals. | 38 item adaptive-response online survey. | 236 (74%) of respondents supported sharing de-identified data via repositories, and 229 (72%) thought investigators should be required to share data on request. 56 (18%) were required to deposit trial data in a repository by funders and 149 (47%) had received an individual request to share data. | |
| Evaluate support and identify major issues for establishing a central repository of individual participant data. | 30 (42%) of 71 reviewers affiliated with the Cochrane Collaboration’s individual participant data meta-analysis method group. | Synopsis and link to 16 question online survey. | 25 (83%) of respondents thought a central repository would be valuable, 25 (83%) would be willing to deposit data in such a repository provided conditions met. |
Principles and Considerations to Inform Best Practices in Ethical Data Sharing.
| Principles and considerations | Reference |
|---|---|
| Ensure sufficiently broad access to realize the benefits to scientific innovation and public health, which are the main justification for sharing. | |
| Data sharing processes must be accountable and transparent. | |
| Equitable: The needs of researchers, secondary users, communities, and funders should be recognized and balanced. | |
| Ensure fair trade and not free trade in data. | |
| Ensure the rights and responsibilities of researchers generating data and data accessors are balanced. | |
| Ensure the benefits of data sharing outweigh the harms, and consider whether restricting the flow of information to avoid rare adverse events is appropriate. | |
| Clearly specify public interests in data sharing and clearly specify any legitimate reasons to restrict access to research data (following market approval of an intervention). | |
| Ensure that the analytic value of the data is preserved during the protection of privacy and confidentiality. | |
| Ensure data sharing processes are responsive to the context within which datasets were collected. | |
| Honor the altruism of research participants. |
Potential Benefits of a Governed Approach to Data Sharing.
| Potential benefits of curation | Reference |
|---|---|
| Adequate safeguards can be established, bona fide access restrictions can be put in place. | |
| Patient privacy is increased. | |
| Poor quality research, which may lead to erroneous conclusions, can be prevented following review and requirements to adhere to a rigorous analytical plan. | |
| Permits compliance with legislation and or regulation. | |
| Promotes adherence to commitments made during the consent process. | |
| Enables researchers to fulfill responsibilities to ensure data are used ethically. | |
| Curation can be responsive to the types of data being shared. Differing approaches can be taken to aggregate and individual-level data, particularly valuable or sensitive datasets, and analyses that require detailed data that could potentially identify participants. |
Priority Areas for Policy Development.
| Areas for policy development | References |
|---|---|
| Appropriate analytic methods, data and meta-data standards, including means of preserving privacy | |
| Determining where, how, when, and which data are archived and made available | |
| Determining for which trials data will be shared, which data and supporting documents will be available, the process for data sharing, how transparent the process will be, who will get access, what types of analyses are permitted, who will decide, what criteria will be used, and what ongoing role the trial sponsor might have. | |
| Methods to permit evaluation of individual applications, including to ensure that the use does not harm participants and is in conformity with ethical approvals | |
| Transparent, explicit, and reasonable criteria for case by case decision making | |
| Requirements and rewards for the collection and curation of datasets for sharing |